Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial carcinoma
• Platinum-refractory or resistant disease
• * At least 1 prior non-platinum chemotherapy agent required
• Prior bilateral salpingo-oophorectomy and hysterectomy required
• Bidimensionally measurable disease OR CA-125 greater than 100 units/mm3
• PATIENT CHARACTERISTICS:
• Age:
• Over 18
• Performance status:
• Karnofsky 70-100%
• Life expectancy:
• More than 3 months
• Hematopoietic:
• Not specified
• Hepatic:
• Bilirubin normal
• AST no greater than 2.5 times upper limit of normal (ULN)
• Renal:
• Creatinine no greater than 1.5 times ULN OR
• Creatinine clearance at least 50 mL/min
• Other:
• No other prior malignancy except non-melanoma skin cancer unless curatively treated with no evidence of disease within the past 5 years and at low risk for recurrence
• No other clinical circumstances that would preclude study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 weeks since prior biologic therapy and recovered
• No prior thalidomide
• Chemotherapy:
• See Disease Characteristics
• At least 4 weeks since prior cytotoxic therapy and recovered
• Endocrine therapy:
• At least 4 weeks since prior hormonal therapy and recovered
• Radiotherapy:
• At least 4 weeks since prior radiotherapy
• Surgery:
• See Disease Characteristics
• At least 4 weeks since prior major surgery